ASPR TRACIE Technical Assistance Request

Request Receipt Date (by ASPR TRACIE): August 19, 2021
Response Date: August 19, 2021
Type of TA Request: Standard

Request:

The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), Technical Resources, Assistance Center, and Information Exchange (TRACIE) Team received a request for a (statewide or regional) prototype of a standing physician's order for monoclonal antibody infusion treatment.

Response:

The ASPR TRACIE Team reviewed our existing resources and conducted a search online for additional relevant materials. All resources gathered are provided in this document.

Please refer to the Centers for Disease Control and Prevention’s Coronavirus Disease 2019 webpage and the National Institutes of Health COVID-19 Treatment Guidelines for the most up-to-date clinical guidance on COVID-19 outbreak management.

For additional questions on monoclonal antibody treatment regimens, contact the HHS ASPR Clinical Team at covid19therapeutics@hhs.gov.

I. Monoclonal Antibody Standing Order Prototypes

The ASPR TRACIE Team is aware of the following two statewide orders that are currently in place:


For a health system version, visit the following website and scroll down to get to the Casirivimab-Imdevimab (REGEN-COV) Medical Director Standing Order Template: https://asap.nebraskamed.com/monoclonal-antibody-project/.

In addition, while not standing orders, the following page includes sample order sets that might be helpful: https://infusioncenter.org/prescribing-and-referral-resources/. Select either Sotrovimab or REGEN-COV and then click on the order sets on their respective pages.
II. Additional Relevant Resources for Monoclonal Antibody Therapy


This resource page provides information about monoclonal antibody therapeutics currently authorized for the treatment of COVID-19, including links to an outpatient administration playbook, a communications toolkit, and a calculator for infusion sites.


This Topic Collection focuses on plans, tools, templates, and other immediately implementable resources to help with COVID-19 preparedness, response, recovery, and mitigation efforts, focusing on outpatient settings.


In this speaker series, Dr. William Fales, MD, FACEP, FAEMS, Medical Director, Michigan Department of Health & Human Services, Division of EMS and Trauma and Professor and Chief, Division of EMS and Disaster Medicine, Western Michigan University describes the statewide approach and support of monoclonal antibody therapy in various healthcare settings.


This tip sheet describes monoclonal antibody therapy for COVID-19 patients and highlights considerations for providers and planning and allocation.


This page links to the emergency use authorization (EUA) Fact Sheets for Health Care Providers for Bamlanivimab and Casirivimab/Imdevimab, and provides information about coding and Medicare payment for monoclonal COVID-19 infusion and about billing for monoclonal antibody COVID-19 infusion administration.


This page provides various resources for clinicians to support the administration of monoclonal antibodies. Resources include provider fact sheets on currently authorized
monoclonal antibody treatments, therapy administration resources, resources for patients, frequently asked questions, and treatment guidelines.


The information in this document can help healthcare staff at the state, tribal, local, and territorial levels prepare to and deliver therapeutic monoclonal infusions against COVID-19 in an outpatient setting.


The summary highlights recommendations for payment, better evidence, and state allocation. The full text of the report is linked from the top of the page.


This two-page handout for patients provides information on monoclonal antibodies, such as the criteria required to receive monoclonal antibody treatment, how the treatment is administered, the list of possible side effects, and other educational information.


This interactive map displays locations across the U.S. that recently received shipments of Bamlanivimab or Casirivimab/Imdevimab to assist clinicians and patients in determining availability of monoclonal antibody treatments.